INTRODUCTION AND OBJECTIVES: To review the incidence, management and survival outcomes of prostate cancer (PCa) among kidney transplant recipients (KTRs) and to compare these characteristics with a national population.
METHODS: A retrospective study was performed on all KTRs subsequently diagnosed with PCa from a National Kidney Transplant Centre . The primary outcome variables were to compare incidence and 5-year overall survival in KTRs with non-KTRs after treatment of PCa. Secondary outcomes variables were PSA at diagnosis, Gleason grade, treatment strategy and morbidity from treatment among KTRs.
RESULTS: 4048 kidney transplants were performed; of which 3020 (63.9%) were male recipients. In total, 34 (1.1%) KTRs were diagnosed with PCa 109AE83 months (range 7-372) after renal transplantation. The age at prostate cancer diagnosis was 64AE7(range: 53-78) years in KTRs, median PSA was 10 (range: 2.6-771 ng/dL) and 76% (n[26/34) were diagnosed with localised disease. The incidence of PCa was 1,126/100,000 males in KTRs compared to 160/1000,000 males in Ireland (p[0.01). Eighteen patients were treated with curative radiotherapy, 2 underwent curative surgery, 8 were treated with androgen deprivation therapy (ADT) and 6 were managed with watchful waiting (WW) protocols. 1-, 3-and 5-year overall survival rates were not significantly different among KTRs diagnosed with PCa compared to national PCa data (98% Vs 98%, 80% Vs 79% and 77% Vs 72% respectively, p[0.8).
CONCLUSIONS: The incidence of PCa is significantly higher among KTRs compared to non KTRs in the general population, with mostly localised disease diagnosed. Outcomes after curative treatment are excellent. Definitive management guidelines should be developed to increase awareness and optimise treatment options in this unique patient cohort.
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MP70-06 PREOPERATIVE ANTIBODY TITER AGAINST BK POLYOMAVIRUS MAY PREDICT BK POLYOMAVIRUS-ASSOCIATED NEPHROPATHY AFTER KIDNEY TRANSPLANTATION
Mitsuru Saito*, Shigeru Satoh, Takuro Saito, Ryohei Yamamoto, Taketoshi Nara, Syuji Chiba, Sohei Kanda, Kazuyuki Numakura, Shintaro Narita, Takamitsu Inoue, Tomonori Habuchi, Akita, Japan INTRODUCTION AND OBJECTIVES: BK polyomavirus (BKPyV) is a causative agent of BKPyV-associated nephropathy (BKPyVAN) and hemorrhagic cystitis, which occurs subsequent to BKPyV reactivation. Intravenous immunoglobulin is presumed to have significant neutralizing activity in vitro; therefore, a high-antibody titer against BKPyV should be effective in controlling BKPyV-associated diseases. This study aimed to measure the preoperative anti-BKPyV antibody titer in both kidney transplant recipients and living donors and investigate the significance of a preoperative anti-BKPyV antibody titer as a clinical marker.
METHODS: From July 2013 to December 2016, 68 consecutive kidney living-donor-recipient pairs underwent kidney transplantation at Akita University Hospital. First, we obtained urine and blood samples of the kidney transplant recipients before and 1, 3, 6, and 12 months after kidney transplantation. Next, we measured the DNA copy number of BKPyV by quantitative real-time polymerase chain reaction. AntiBKPyV antibody titers of the serum of both recipients and living donors were evaluated preoperatively by neutralizing activity using enzyme-linked immunosorbent assay.
